ProCE Banner Activity

MONALEESA-3: Updated Overall Survival Analysis of Ribociclib + Fulvestrant vs Placebo + Fulvestrant in Postmenopausal Patients With HR+/HER2- Advanced Breast Cancer

Slideset Download
Conference Coverage
In this exploratory analysis performed at a median follow-up of approximately 4.5 years, ribociclib + fulvestrant maintained OS benefit vs placebo + fulvestrant in postmenopausal patients with HR+/HER2- advanced breast cancer.

Released: June 11, 2021

Expiration: June 10, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme